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A B S T R A C T
Background
Irreversible pulpitis, which is characterised by acute and intense pain, is one of the most frequent reasons that patients attend for
emergency dental care. Apart from removal of the tooth, the customary way of relieving the pain of irreversible pulpitis is by drilling
into the tooth, removing the inflamed pulp (nerve) and cleaning the root canal. However, a significant number of dentists continue to
prescribe antibiotics to stop the pain of irreversible pulpitis.This review updates the previous version published in 2016.
Objectives
To assess the effects of systemic antibiotics for irreversible pulpitis.
Search methods
We searched Cochrane Oral Health’s Trials Register (to 18 February 2019); the Cochrane Central Register of Controlled Trials
(CENTRAL; 2019, Issue 1) in the Cochrane Library (searched 18 February 2019); MEDLINE Ovid (1946 to 18 February 2019);
Embase Ovid (1980 to 18 February 2019); US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (searched 18
February 2019); and the World Health Organization International Clinical Trials Registry Platform (searched 18 February 2019).
There were no language restrictions in the searches of the electronic databases.
Selection criteria
Randomised controlled trials which compared pain relief with systemic antibiotics and analgesics, against placebo and analgesics in the
acute preoperative phase of irreversible pulpitis.
Data collection and analysis
Three review authors screened studies and extracted data independently. We assessed the certainty of the evidence of included studies
using GRADE. Pooling of data was not possible and a descriptive summary is presented.
Main results
No additional trials could be included in this update. One trial at low risk of bias evaluating oral penicillin in combination with
analgesics versus placebo with analgesics, involving 40 participants was included in a former update of the review. The certainty of
the evidence was rated low for the different outcomes. Our primary outcome was patient-reported pain (intensity/duration) and pain
relief. There was a close parallel distribution of the pain ratings in both the intervention (median 6.0, interquartile range (IQR) 10.5),
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and for placebo (median 6.0, IQR 9.5) over the seven-day study period. There was insufficient evidence to claim or refute a benefit for
penicillin for pain intensity. There was no significant difference in the mean total number of ibuprofen tablets over the study period:
9.20 (standard deviation (SD) 6.02) in the penicillin group versus 9.60 (SD 6.34) in the placebo group; mean difference -0.40 (95%
confidence interval (CI) -4.23 to 3.43; P = 0.84). This applied equally for the mean total number of Tylenol tablets: 6.90 (SD 6.87)
used in the penicillin group versus 4.45 (SD 4.82) in the placebo group; mean difference 2.45 (95% CI -1.23 to 6.13; P = 0.19). Our
secondary outcome on reporting of adverse events was not addressed in this study.
Authors’ conclusions
This Cochrane Review which was based on one low-powered small sample trial assessed as at low risk of bias, illustrates that there is
insufficient evidence to determine whether antibiotics reduce pain or not compared to not having antibiotics. The results of this review
confirm the necessity for further larger sample and methodologically sound trials that can provide additional evidence as to whether
antibiotics, prescribed in the preoperative phase, can affect treatment outcomes for irreversible pulpitis.
P L A I N L A N G U A G E S U M M A R Y
Antibiotic use for severe toothache (irreversible pulpitis)
Review question
Are oral antibiotics effective and safe for treating pain in irreversible pulpitis (inflammation of the nerve inside the tooth/nerve damage)?
Background
Irreversible pulpitis occurs where the dental pulp (tissue inside the tooth which contains the nerve) has been damaged beyond repair.
It is characterised by intense pain (toothache), sufficient to wake someone up at night and is considered to be one of the most frequent
reasons that patients attend for emergency dental care. Any tooth may be affected, it is not restricted to particular age groups, and it
usually occurs as a direct result of dental decay, a cracked tooth, or trauma.
The ’standard of care’ for irreversible pulpitis - immediate removal of the pulp from the affected tooth - is now widely accepted and yet
in certain parts of the world antibiotics continue to be prescribed.
Study characteristics
The evidence on which this review is based was current as of 18 February 2019. One study involving 40 people with irreversible pulpitis
(nerve damage) was included. There were two groups of 20 people, one group was treated with penicillin 500 mg, the other with
placebo (no active ingredient) every six hours over a seven-day period. In addition, all of the participants received painkillers (ibuprofen
and paracetamol (acetaminophen) combined with codeine).
Key results
Antibiotics do not appear to significantly reduce toothache caused by irreversible pulpitis. Furthermore, there was no difference in the
total number of ibuprofen or Tylenol tablets used over the study period between both groups. The administration of penicillin does not
significantly reduce the pain perception, the percussion (tapping on the tooth) perception, or the quantity of pain medication required
by people with irreversible pulpitis. There was no reporting on adverse events or reactions.
Certainty of the evidence
This was a study with a small number of participants and the certainty of the evidence for the different outcomes was rated as low.
There is currently insufficient evidence to be able to decide if antibiotics help for this condition. This review highlights the need for
more and better quality studies on the use of antibiotics for irreversible pulpitis.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antibiotics for irreversible pulpitis
Patient or population: pat ients with irreversible pulpit is
Settings: dental clinic
Intervention: ant ibiot ics
Control: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Antibiotics
Patient- reported pain
intensity
(sum of pain inten-
sity dif f erence (SPID)
and sum of pain per-
cussion intensity dif f er-
ence (SPPID))
Follow-up: 7 days
The in between-group dif ferences (median ± IQR) in SPID for the penicill in
group were 6.0 ± 10.5, and for placebo 6.0 ± 9.5
The SPPID for the penicill in group was 3.5 ± 7.5 and for placebo 2.0 ± 7.0
40
(1 study)
⊕⊕©©
low1
The in-between group
dif ferences in SPID and
SPPID were not stat ist i-
cally signif icant2
Patient- reported pain
relief
Outcome not reported
Total number of
ibuprofen tablets
Follow-up: 7 days
The mean total number
of ibuprofen tablets in
the control groups was
9.60 tablets
The mean total number
of ibuprofen tablets in
the intervent ion groups
was 0.40 lower
(4.23 lower to 3.43
higher)
- 40
(1 study)
⊕⊕©©
low3
The administrat ion of
penicill in over placebo
did not appear to signif -
icant ly reduce the quan-
t ity of ibuprofen con-
sumed for irreversible
pulpit is
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Total number of parac-
eta-
mol (acetaminophen) +
codeine tablets
Follow-up: 7 days
The mean total num-
ber of acetaminophen +
codeine tablets in the
control groups was 4.
45 tablets
The mean total num-
ber of acetaminophen
+ codeine tablets in
the intervent ion groups
was 2.45 higher
(1.23 lower to 6.13
higher)
- 40
(1 study)
⊕⊕©©
low3
The administrat ion of
penicill in over placebo
did not appear to sig-
nif icant ly reduce the
quant ity of Tylenol con-
sumed for irreversible
pulpit is
Number of adverse
events
Outcome not reported
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95%CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95%CI)
CI: conf idence interval; IQR: interquart ile range
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded 2 levels for very serious imprecision (very small sample size).
2The between-group dif ferences in SPID (median; IQR) for the penicill in group were 6.0 ± 10.5 and for placebo 6.0 ± 9.5, P =
0.776. The SPPID (median; IQR) for the penicill in group were 3.5 ± 7.5 and placebo 2.0 ± 7.0, P = 0.290.
3Downgraded 2 levels for very serious imprecision (very small sample size and 95% CI includes no ef fect and both the upper
and lower conf idence lim it crosses the minimal important dif f erence).
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B A C K G R O U N D
Dental emergencies are extremely common. A survey conducted
in the UK recorded that 16% of the population had experienced
toothache in the preceding year (Steele 2011).Non-traumatic den-
tal condition visits account for 1.4% of all emergency department
visits in the USA and have shown an annual rise of 4% (from
1% in 1997 to 1.7% in 2007) (Onkunseri 2012). Dental caries
(tooth decay) is the result of bacterial attack on a tooth and is
the precursor to irreversible pulpitis, which is considered to be an
immune system mediated event affecting the dental pulp (nerve)
rather than an infective condition of the pulp (Bergenholtz 1990).
Acute and intense pain are the most typical presenting symptoms
of irreversible pulpitis. It occurs more commonly in vital teeth
beneath deep caries before the bacteria have even reached the pulp
(Hahn 1991). Thus the involved tooth will usually have an exten-
sive restoration (filling) or caries or both under which death of the
pulp may occur quite quickly or which may take years to occur
even if the dental caries is removed (Tronstad 1991).
Description of the condition
Irreversible pulpitis is caused by a vital inflamed pulp which is
incapable of healing (Hargreaves 2015). The symptoms are a con-
tinuum and can vary but usually include a history of spontaneous
pain which may also involve an exaggerated response to hot or
cold that lingers after the stimulus is removed (Soames 1998). Any
tooth may be affected by irreversible pulpitis, it is not restricted
to particular age groups and occurs as a direct result of dental
caries, a cracked tooth, or trauma. The involved tooth is usually
not sensitive to percussion, and palpation tests do not produce an
untoward reaction. The characteristics of irreversible pulpitis are
a vital pulp which responds to cold and electric pulp testing. A
number of variations of irreversible pulpitis have been recognised
(Hargreaves 2015). These include acute, subacute, chronic, partial
or total, infected or sterile, however it is not possible to clearly
differentiate these except by histopathological methods.
Description of the intervention
Although not indicated by current guidance, it is recognised that a
range of oral antibiotics with differing dosing regimens may in fact
be prescribed (SDCEP 2016). Antibiotics commonly prescribed
by dentists include: ß-lactams (amoxicillin, penicillin V, co-amox-
iclav), macrolides, tetracyclines, clindamycin, and metronidazole
(Dar-Odeh 2010).
How the intervention might work
Pulpitis is an inflammatory reaction of the pulp and often occurs
without any evidence of bacteria in the pulp chamber. Antibiotics
have bactericidal or bacteriostatic properties or both, and are used
widely to control or eliminate bacteria, but themode of action and
extent to which antibiotics have an anti-inflammatory or analgesic
effect in irreversible pulpitis remains less clear.
Why it is important to do this review
There is limited and what appears to be largely anecdotal evidence
to support the routine prescribing of antibiotics for irreversible
pulpitis. It is likely that the practice of prescribing of antibiotics
may have arisen due to a misconception of the natural patholog-
ical process of pulpitis (pain resolves when the pulp devitalises
irrespective of antibiotic use), or the perception that antibiotics
should be prescribed prophylactically in anticipation of pain aris-
ing prior to endodontic treatment. Either of these approaches may
have promoted the inappropriate prescribing of antibiotics for en-
dodontic emergencies. A study conducted in the USA of mem-
bers of the American Association of Endodontists (AAE) surveyed
their prescribing practices and reported that 16.7% of the spe-
cialist endodontists prescribed antibiotics for cases of irreversible
pulpitis (Yingling 2002). A similar study in Spain with mem-
bers of the Spanish Endodontic Society found a figure of 40%
(Rodriguez-Núñez 2009). General dental practitioners are often
the first point of contact for patients with irreversible pulpitis and
although one study conducted in Belgium reported that a smaller
proportion (4.3%) of general dentists continue to prescribe an-
tibiotics for irreversible pulpitis (Mainjot 2009), another study
conducted in Spain indicated that a substantial number (86%) of
respondents continue to do so (Segura-Egea 2010). A more re-
cent study in UK general dental practices found 19.4% of dental
antibiotics were prescribed for irreversible pulpitis (Cope 2016),
whilst a UK dental hospital’s acute dental care department audit
found 70% of antibiotics prescribed for pulpitis in the first cycle
of a clinical audit and 20% in the second cycle (Chopra 2014).
To further investigate the prescribing behaviours of the general
dentists and endodontists, we conducted a survey with the same
question as of this review and found that one in every four dentists
would prescribe antibiotics, when not needed (Agnihotry 2014a).
In a more recent study (Cope 2016), it was found out that more
than half of the sample size of general dentists (65.6%) prescribed
antibiotics when there was no evidence of spreading infection.
Unnecessary use of antibiotics is driving the global increase in
drug-resistant infections and action is required across government
and society including health care and agriculture (O’Neill 2016).
Antibiotics are the corner stone of modern medicine; without ef-
fective antibiotics the success of major surgery and cancer chemo-
therapy will be compromised (WHO 2018). Life-threatening in-
fections caused by Klebsiella pneumoniae which are now resistant
to the last resort treatment (carbapenems) have spread worldwide;
treatment failure to the last resort of medicine for gonorrhoea
(third generation cephalosporin antibiotics) has been confirmed
in at least 10 countries (Australia, Austria, Canada, France, Japan,
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Norway, Slovenia, South Africa, Sweden, and the UK (WHO
2018). By 2050, it is expected that deaths from antimicrobial resis-
tant infections will be higher than from cancer (O’Neill 2016). Al-
though the inappropriate prescribing of antibiotics for endodontic
emergencies has receivedmuch attention (Agnihotry 2014; Fouad
1996; Palmer 2003; Segura-Egea 2018), it remains unclear towhat
extent this may have contributed to the development of resistant
strains of bacteria and the growing problem of antibiotic resistance
(CDC 2008; SMAC 1997).
Other adverse events associated with dental antibiotic use have
been reported, including its contribution to the incidence of
Clostridium difficile in the community (Bye 2017). Antibiotic-re-
lated colitis caused by C diff is associated with significant mor-
bidity and can be life threatening, especially for elderly and med-
ically compromised patients (Beacher 2015). Increasing rates of
anaphylaxis to antibiotics have also been reported (Turner 2015).
Irreversible pulpitis, at least in the early phase, is not normally ac-
companied by the clinical signs of bacterial infection, i.e. swelling
and tenderness of adjacent mucosa, which more generally mani-
fests itself after the pulp has become necrotic and the infected pul-
pal tissues pass into the periapical region (Cope 2018). Although
some dentists continue to prescribe antibiotics, there appears to
be very limited evidence that penicillin reduces pain, percussion
sensitivity, or the amount of analgesics required in untreated teeth
diagnosed with irreversible pulpitis (Nagle 2000).
Immediate pulpectomy is now widely accepted as the ’standard
of care’ for irreversible pulpitis (Segura-Egea 2018; Walton 2009)
and yet in certain parts of the world antibiotics continue to be
prescribed. We consider that a systematic review is still necessary
to provide further evidence of the effects of antibiotics and ulti-
mately more clarity and guidance in the management of this clin-
ical condition.This review updates the previous version published
in 2016 (Agnihotry 2016).
O B J E C T I V E S
To assess the effects of systemic antibiotics for irreversible pulpitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) were considered in this re-
view.
Types of participants
We included adult patients who were over the age of 18 and pre-
sented with a single tooth with a clinical diagnosis of irreversible
pulpitis.
Types of interventions
Active interventions
Administration of any systemic antibiotic at any dosage and any
analgesic at any dosage prescribed in the acute preoperative phase
of irreversible pulpitis.
Control
Administration of placebo and any analgesic, at any dosage, pre-
scribed in the acute preoperative phase of irreversible pulpitis.
Types of outcome measures
Primary outcomes
• Patient-reported pain (intensity/duration) and pain relief
measured on a categorical scale in the preoperative phase of
irreversible pulpitis.
Secondary outcomes
• Type, dose, and frequency of medication required for pain
relief.
• Any adverse effects related to any clinically diagnosed
hypersensitivity or other reactions to either the antibiotics or
analgesics.
Search methods for identification of studies
Electronic searches
Cochrane Oral Health’s Information Specialist conducted system-
atic searches in the following databases for randomised controlled
trials and controlled clinical trials. There were no language, pub-
lication year or publication status restrictions.
For this update we searched the following databases:
• Cochrane Oral Health’s Trials Register (searched 18
February 2019) (Appendix 1);
• the Cochrane Central Register of Controlled Trials
(CENTRAL; 2019, Issue 1) in the Cochrane Library (searched
18 February 2019) (Appendix 2);
• MEDLINE Ovid (1946 to 18 February 2019) (Appendix
3);
• Embase Ovid (1980 to 18 February 2019) (Appendix 4).
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Subject strategies were modelled on the search strategy designed
for MEDLINE Ovid.
Searching other resources
The following trial registries were searched for ongoing studies
(see Appendix 5 for the search strategy):
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (searched 18 February 2019);
• World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch; searched 18
February 2019).
Only handsearching done as part of the Cochrane worldwide
handsearching programme and uploaded to CENTRAL was in-
cluded.
We searched reference lists of relevant articles and clinical trials in
an attempt to identify any potential or additional studies.
We did not perform a separate search for adverse effects of inter-
ventions used, we considered adverse effects described in included
studies only.
Data collection and analysis
Selection of studies
Three review authors independently assessed the titles and ab-
stracts of studies resulting from the searches. All irrelevant records
were excluded and only details of potential studies were noted.
Full copies were obtained of all relevant and potentially relevant
studies which appeared to meet the inclusion criteria, or when
there were insufficient data in the title and abstract to make a
clear decision. Studies not matching our inclusion criteria were ex-
cluded and their details and reasons for their exclusion were noted
in the Characteristics of excluded studies table in ReviewManager
(RevMan) (Review Manager 2014).
Data extraction and management
Study details were entered into the Characteristics of included
studies table. We collected outcome data using a predetermined
form and entered them into RevMan. The review authors only
included data if there was an independently reached consensus.
All disagreements were resolved by discussion.
We extracted the following details.
• Study methods: method of allocation, masking of
participants and outcomes.
• Participants: country of origin, sample size, age, sex,
inclusion and exclusion criteria.
• Intervention: type of antibiotic.
• Control: analgesic, placebo or nil.
• Outcomes: primary and secondary outcomes as described
in the Types of outcome measures section of this review.
Assessment of risk of bias in included studies
Each of two review authors then graded the selected studies sepa-
rately according to the domain-based evaluation described in the
Cochrane Handbook for Systematic Reviews of Interventions 5.1.0
(updated March 2011) (Higgins 2011). The gradings were com-
pared and any inconsistencies between the review authors were
discussed and resolved.
The following domains were assessed as at ’low risk’ of bias (i.e.
plausible bias unlikely to seriously alter the results), ’unclear’ (i.e.
uncertain risk of bias, plausible risk of bias that raises some doubts
about the results), or ’high risk’ of bias (plausible bias that seriously
weakens confidence in the results):
• sequence generation;
• allocation concealment;
• blinding (of participants, personnel and outcomes
assessors);
• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias.
We categorised and reported the overall risk of bias in the included
study according to the following:
• low risk of bias (plausible bias unlikely to seriously alter the
results) if all criteria were met;
• unclear risk of bias (plausible bias that raises some doubt
about the results) if one or more criteria were assessed as unclear;
or
• high risk of bias (plausible bias that seriously weakens
confidence in the results) if one or more criteria were not met.
These assessments are reported for the included study in the
Characteristics of included studies table.
Measures of treatment effect
The trialists in Nagle 2000 used sum of pain intensity difference
(SPID) and sum of pain percussion intensity difference (SPPID)
to assess between-group differences. Values were expressed as me-
dians with interquartile ranges and were analysed using theMann-
Whitney-Wilcoxon test. Each patient was asked to rate their pain
on a scale from 0 to 3 (0 = no pain; 1 = mild pain, pain that was
recognizable but not discomforting; 2 = moderate pain, pain that
was discomforting but bearable; 3 = severe pain, pain that caused
considerable discomfort and was difficult to bear). Patients were
asked to rate the pain to percussion using the same scale. SPID
is defined as the sum of pain intensity differences weighted by
the length of the interval since the previous observation. These
assessments were made at wake-up time over the seven-day study
period. We were unsuccessful in our attempts to contact the inves-
tigators to provide us with means or ranges of the minimum and
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maximum scores for SPID and SPPID, and therefore we were un-
able to calculate and present means, standard deviations and con-
fidence intervals for these outcomes. These have been discussed
narratively based on the data as reported in the study (see Effects
of interventions).
We have presented the continuous outcomes on the original scale
as reported in the study for our secondary outcome ’number of
painkillers’ togetherwith their associated 95%confidence intervals
(CIs). These data were analysed in RevMan (Review Manager
2014) using a random-effects model.
For future studies we will present continuous outcomes on the
original scale as reported in each individual study. If similar out-
comes were reported using different scales, we would convert these
to standardized mean differences (SMD).
We will present dichotomous outcomes as risk ratios (RR), and if
found significant, we would convert them to the number needed
to treat (NNT) to find one success. We will report all outcomes’
data with their associated 95% CIs and analyse the data using
a random-effects model in RevMan, with a general inverse vari-
ance (DerSimonian and Laird method), unless stated otherwise.
In cases where only medians are presented with ranges, the mean
is estimated by the median, and the variance using the range and
the number of observations (Hozo 2005).
Unit of analysis issues
It is possible that studies included in future updates may present
data from repeated observations on participants which may lead
to unit of analysis errors, if so we will follow the advice provided
in section 9.3.4 of the Cochrane Handbook for Systematic Reviews
of Interventions ( Higgins 2011).
Dealing with missing data
There were nomissing data in the single included study. For future
updates, if data are missing attempts will be made to contact the
trial investigators.
Assessment of heterogeneity
There was only one single trial and therefore no assessments were
made.
If further studies are included in future updates, we will assess
clinical heterogeneity by examining the characteristics of the stud-
ies, the similarity between the types of participants, the interven-
tions and outcomes as specified in the criteria for included studies.
Statistical heterogeneity will be assessed using a Chi2 test and the
I2 statistic where I2 values over 60% indicate moderate to sub-
stantial heterogeneity (Higgins 2011). If this could be explained
by clinical reasoning and a coherent argument can be made for
combining the studies, we will enter these into a meta-analysis. In
cases where the heterogeneity could not be adequately explained,
the data will not be pooled. A cut off P value of > 0.10 would be
used to determine statistical significance.
Assessment of reporting biases
If a sufficient number (> 10) of trials investigating similar inter-
ventions are identified for inclusion in future updates of this re-
view, publication bias will be assessed according to the recommen-
dations on testing for funnel plot asymmetry as described in sec-
tion 10.4.3.1 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). If asymmetry is identified, we will
try to assess other possible causes and these will be explored in the
discussion if appropriate.
Data synthesis
If further studies are included the following methods of data syn-
thesis will apply.Data will be analysed using RevMan and reported
according to Cochrane criteria. Pooling of data will only occur if
the included studies have similar interventions involving similar
participants. We will present risk ratios for outcomes and odds
ratios for adverse effect outcomes. The risk ratio is the ratio of the
risk of an event in the two groups whereas the odds ratio is the
ratio of the odds of an adverse event in the intervention group to
the odds of an event in the control group. Additionally, any data
obtained from visual analogue scales and any categorical outcomes
will be transformed into dichotomous data prior to analysis if ap-
propriate. Risk ratios, the number needed to treat and their 95%
confidence intervals will be calculated for all dichotomous data.
Subgroup analysis and investigation of heterogeneity
If a sufficient number of studies with moderate to substantial het-
erogeneity (as defined above) are identified we will carry out sub-
group analyses based on different antibiotics and dosing regimens.
Sensitivity analysis
We had expected to be able to conduct sensitivity analyses to assess
the robustness of our review results by repeating the analysis with
the following adjustments: exclusion of studies at high risk of bias
and unpublished studies. However, as there was only a single trial
that matched our inclusion criteria no sensitivity analyses were
carried out.
Summary of findings
We developed a ’Summary of findings’ table following GRADE
methods (GRADE 2004) and using GRADEproGDT software
(GRADEpro GDT 2015) for the following outcomes listed ac-
cording to priority.
• Patient-reported pain intensity (sum pain intensity
differences and sum pain percussion intensity differences).
• Patient-reported pain relief.
• Total number of ibuprofen tablets.
• Total number of paracetamol (acetaminophen) + codeine
tablets.
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• Number of adverse events.
The certainty of the body of evidence was assessed with reference
to the overall risk of bias of the included study, the directness of
the evidence, the inconsistency of the results, the precision of the
estimates, the risk of publication bias, and the magnitude of the
effect. We categorised the certainty of the body of evidence for
each outcome as high, moderate, low, or very low.
R E S U L T S
Description of studies
Results of the search
The search strategy used in the first version of this review in 2005
identified 39 references of which all but four were excluded from
further analysis. Full-text copies of these four papers were obtained
for further assessment. Only one study (Nagle 2000) met the in-
clusion criteria and is included in the review. No additional studies
were identified for inclusion based on subsequent updated searches
in February 2009, September 2013, January 2016, or February
2019 (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Methods
Nagle 2000 is a randomised double-blind placebo-controlled clin-
ical trial conducted in the emergency department of a university
dental college in the USA.
Participants and setting
Forty adult patients, 17 male, 23 female, with an age range of 30
to 34 years who had presented as an emergency with spontaneous
moderate to severe pain associated with a tooth, participated in
this study. All of the teeth were vital and responsive to an elec-
tric pulp tester (EPT) and to Endo Ice and displayed percussion
sensitivity. The diagnosis of irreversible pulpitis was confirmed by
a radiographically widened periodontal ligament space (see Addi-
tional Table 1).
Intervention
Twenty participants were allocated to antibiotic and analgesic and
20 to placebo and analgesic. The participants received a seven-day
oral dose (28 capsules each to be taken every six hours) of either
penicillin (500 mg) or a placebo control in which the participants
and trialists were double-blinded. They also received a supply of
pain medication consisting of ibuprofen 600 mg; paracetamol (ac-
etaminophen) with codeine 30 mg (Tylenol). No operative en-
dodontic treatment was performed during the course of the study.
Outcomes
The primary outcome for this review was pain relief in the preop-
erative phase of irreversible pulpitis. Participants in this study were
requested to complete a seven-day diary in which they recorded
pain, percussion pain, and the quantity and type of pain medica-
tion taken. Pain was assessed using a short ordinal numerical scale
graded from 0 to 3 (see Measures of treatment effect). Addition-
ally, the patients were asked to use the same scale to rate pain on
percussion which was achieved by tapping the affected tooth with
a finger. The pain scale used in this trial had been used in previous
pain studies which were referenced by the trialists of the included
study.
The secondary outcome was the type and dose of pain medication
required to achieve pain relief. The participants in this study were
instructed to initially take one tablet of the ibuprofen every four
to six hours as needed for pain and to take the Tylenol (two tablets
every four to six hours) only if the ibuprofen did not relieve their
pain. Each participant received a seven-day diary to record their
symptoms and the number and type of painmedication taken. No
assessments of adverse effects to either the antibiotics or analgesics
were considered or reported by the investigators.
Excluded studies
Three studies were excluded: a systematic review (Matthews 2003)
which included a potential trial (Henry 2001) which was sub-
sequently excluded as it investigated the effect of antibiotics on
postoperative endodontic pain. One trial (Fouad 1996) was ex-
cluded as it combined the interventions with immediate opera-
tive endodontic treatment. We excluded Nusstein 2003 because it
was a retrospective non-experimental study, see Characteristics of
excluded studies for further details.
Risk of bias in included studies
The single included study (Nagle 2000) met all of the criteria
across all of the domains in Cochrane’s tool for assessing the risk
of bias, and therefore this study was considered to be at low risk of
bias (plausible bias unlikely to seriously alter the results) (Figure
2).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Sequence generation
In this study the intervention (penicillin) and control (placebo)
groups were assigned before the experiment by using four-digit
numbers from a random number table. The method used to gen-
erate the allocation sequence was described in sufficient detail;
therefore, this domain was judged as at low risk of bias.
Allocation concealment
To ensure adequate concealment only the random numbers were
recorded on the data collection and postoperative diary sheets and
it was unlikely that allocation could be foreseen and therefore this
domain was judged as at low risk of bias.
Blinding
Themeasures used to blind study participants and personnel from
knowledge of which intervention a participant received as well as
blinding of outcomes assessors were described in sufficient detail.
The medications were blinded, randomised, and packaged by a
pharmacy. Each 500 mg gelatin capsule of either penicillin or
placebo was identical in form. The 500mg tablets of penicillin VK
were ground into a powder and placed into the clear, unlabelled
gelatin capsules. The white powder of the lactose placebo was
indistinguishable from the white powder of the penicillin tablets
when viewed through the capsule.
Incomplete outcome data
The report was complete and there were no missing data and this
domain was judged as at low risk of bias.
Selective reporting
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There was no evidence of selective outcome reporting and the
outcomes listed in the methods section were comparable to the
reported results. This was judged as at low risk of bias.
Other potential sources of bias
There was no evidence of other potential sources of bias in the
report of the included trial.
Effects of interventions
See: Summary of findings for the main comparison Antibiotics
for irreversible pulpitis
The single included study (Nagle 2000) did not provide sufficient
data to perform a statistical analysis on the primary outcome and
the only data presented are those which were published in the
study. Unsuccessful attempts to obtain additional and individual
level data from the trialists made it difficult to confirm the results
presented in their study (see Measures of treatment effect).
Oral penicillin in combination with analgesics versus
placebo with analgesics
Primary outcome: patient-reported pain
(intensity/duration) and pain relief
Baseline data indicated that all of the participants that entered
the study had moderate to severe pain (Additional Table 1). Af-
ter the first day of the study the average pain rating decreased
and remained quite stable over the following six days. This ini-
tial decrease in pain may be considered to be due to the effect of
the analgesics which was sustained by the gradual and progressive
necrosis of the pulp. However, at the end of the study period and
at the commencement of operative endodontic treatment it was
found that 75% of the teeth in the penicillin group and 80% in
the placebo were still vital.
There was a close parallel distribution of the pain ratings in both
the intervention and placebo groups over the seven days. The
following data were presented as medians with their interquartile
range. The in between-group differences in sum of pain intensity
difference (SPID) for the penicillin group were 6.0 ± 10.5, and
for placebo 6.0 ± 9.5, P = 0.776. The sum of pain percussion
intensity difference (SPPID) for the penicillin group was 3.5 ±7.5
and placebo 2.0 ± 7.0, P = 0.290, with differences as assessed by the
Mann-Whitney-Wilcoxon test considered by the investigators of
the study to be statistically significant at P < 0.05 (Additional Table
2). (See Measures of treatment effect for additional information
on these data.)
Secondary outcome: type, dose and frequency of
medication required for pain relief
The number, percentage and average use and non-use of ibuprofen
and Tylenol are summarised in Additional Table 3.
On both day one and day two only one participant did not take
either one or other of the analgesic medications. The number not
taking any medication increased to three to four (15% to 20%)
on day three, and two to six (10% to 30%) on day four. On the
fifth to seventh days only four to seven (20% to 35%) did not
take any additional pain medication. At day seven, 20% of the
penicillin group and 35% of the placebo group took no additional
analgesics.
There was no significant difference in the mean total number of
ibuprofen tablets over the study period: 9.20 (standard deviation
(SD) 6.02) in the penicillin group versus 9.60 (SD 6.34) in the
placebo group; mean difference -0.40 (95% confidence interval
(CI) -4.23 to 3.43; P = 0.84). The same was true for themean total
number of Tylenol tablets: 6.90 (SD 6.87) in the penicillin group
versus 4.45 (SD 4.82) in the placebo group; mean difference 2.45
(95% CI -1.23 to 6.13; P = 0.19). There was insufficient evidence
to determine whether penicillin reduced the quantity of analgesic
medication or not.
Secondary outcome: adverse events
Not assessed.
D I S C U S S I O N
Summary of main results
The results of this well constructed but underpowered trial of 20
participants in each study arm indicate that the administration of
penicillin did not appear to significantly (P > 0.05) reduce either
the pain perception, the percussion perception, or the quantity of
analgesicmedication required by patientswith irreversible pulpitis.
Our secondary outcome regarding adverse events or reactions was
not addressed. The certainty of the evidence was rated low for the
different outcomes. For further details see Summary of findings
for the main comparison.
The significance of the relatively common occurrence of
toothache, the prevalence of inappropriate prescribing of antibi-
otics with the potential for producing antibiotic resistance and
patient sensitisation cannot be underestimated. It was somewhat
disappointing to see that only one single trial matched our inclu-
sion criteria.
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Overall completeness and applicability of
evidence
The single included study (Nagle 2000) provides insufficient evi-
dence that the administration of antibiotics is effective in relieving
the pain from irreversible pulpitis. However, although we consider
that the population, intervention, comparator to the intervention,
and outcome of interest satisfy the clinical question of our review,
the lack of further research since this study was conducted, which
is still highly desirable, would appear to indicate that there is a
wider acceptance that the ’standard of care’ and appropriate man-
agement strategy for irreversible pulpitis is immediate extirpation
of the pulp.
Quality of the evidence
The certainty of the evidence as summarised in Summary of
findings for the main comparison was rated as low. The most im-
portant reasons for downgrading for each outcome were: impre-
cision, mainly due to low sample size and the 95% confidence in-
terval included no effect and the upper or lower confidence limit
crossed the minimal important difference.
Limitations in study design and implementation
We did not identify any limitations in either the design or imple-
mentation of the study (Figure 2). However, adverse events were
not addressed in this study.
Indirectness of the evidence
Although limited to a single study, the evidence canbe directly gen-
eralized to the clinical scenario of the presentation of irreversible
pulpitis.
Inconsistency of the results
The single included study did not allow any assessment of incon-
sistency of results.
Imprecision of the results
The single studywith a low sample size included in this review pro-
vided limited amounts of data. Our primary outcome was down-
graded due to small sample size, and due to the sparse data we were
unable to further evaluate the imprecision of the results. However,
for our secondary outcome we downgraded twice as the confi-
dence intervals included no effect and both the upper and lower
confidence limit crossed the minimal important difference.
Publication bias
Although it would be reasonable to assume that the comprehensive
searches will have identified all existing randomised controlled
trials, and thereby helped to limit bias in the conduct of this review,
the absence of any published trials over the last 10 years creates
a measure of uncertainty that there may be further and as yet
unpublished studies which might add to the overall evidence.
Potential biases in the review process
We made every attempt to limit bias in the review process by
ensuring a comprehensive search for potentially eligible studies.
The authors’ independent assessments of eligibility of studies for
inclusion in this review minimised the potential for selection bias.
The effects of language bias on the identification and selection of
studies for inclusion in a systematic review is widely recognised;
therefore, we ensured that language of publication was not used
as an exclusion criterion.
Agreements and disagreements with other
studies or reviews
Our electronic searches did identify two systematic reviews
(Aminoshariae 2016; Matthews 2003) which offered strong con-
firmatory evidence that in the absence of systemic complications
e.g. fever, lymphadenopathy, cellulitis or in immunocompromised
patients, antibiotics alone have no place in the management of lo-
calised acute apical abscess. Furthermore, they stated that although
the pain from acute apical abscess is as a result of an infective pro-
cess, the infection is localised and that even in this terminal stage
of irreversible pulpitis the use of antibiotics as a sole or concomi-
tant therapy remains questionable.
In our search for additional studies and reviews, we also ex-
amined several clinical references and sources for guidelines
and systematic reviews: Agency for Healthcare Research and
Quality ( www.ahrq.gov), National Guidelines Clearinghouse (
www.guideline.gov),National Institute forHealth andCare Excel-
lence ( www.nice.org.uk), Scottish Intercollegiate Guidelines Net-
work ( www.sign.ac.uk/index.html), UK Database of Uncertain-
ties about the Effects of Treatments ( www.library.nhs.uk/duets),
and UpToDate ( www.uptodate.com/home). It was surprising to
find that the majority did not address this clinical topic or pro-
vided very limited useful or current information that could aid
clinical decision-making.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
This review illustrates that there is insufficient evidence to deter-
mine whether antibiotics reduce pain or not when compared to
not having antibiotics. The certainty of the evidence for the dif-
ferent outcomes was low, mainly due to imprecision of the data.
Although there was a paucity of high-certainty evidence to guide
clinical practice, the prescribing of antibiotics for irreversible pul-
pitis should not be seen as a substitute for immediate pulpectomy
which is now widely accepted as the ’standard of care.’
Implications for research
The results of this Cochrane Review confirm the necessity for
further larger sample and methodologically sound trials that can
help provide additional evidence as to whether antibiotics can
affect treatment outcomes for irreversible pulpitis.
Any future randomised controlled trials must be well-designed,
well-conducted, and adequately delivered with subsequent report-
ing, including high-quality descriptions of all aspects of method-
ology. Reporting should conform to the CONSORT statement (
www.consort-statement.org) which will enable appraisal and in-
terpretation of results, and accurate judgements to be made about
the risk of bias, and the overall certainty of the evidence.
Although it is uncertain whether reported quality mirrors actual
study conduct, it is noteworthy that studies with unclear method-
ology have been shown to produce biased estimates of treatment
effects (Schulz 1995).
For further research recommendations based on the EPICOT
(evidence, population, intervention, comparison, outcomes, and
time) format (Brown 2006), see Additional Table 4. However, it
may be more appropriate for future research to concentrate on
pain control rather than prescription of antibiotics.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Nagle 2000
Methods Prospective randomised double-blind trial in the USA. Before the experiment, patient
groups (penicillin or placebo) were assigned by using 4-digit numbers from a random
number table. Only the random numbers were recorded on the data collection and
postoperative diary sheets to blind the experiment.
The medications were blinded, randomised, and packaged by a pharmacy
Participants Adults: (40) 17 male, 23 female. Mean age and standard deviation (SD) in the penicillin
group 30 (9.8), placebo group 34 (11.6).
2 groups of 20: penicillin group 7 women and 13 men, placebo 16 women and 4 men
Inclusion criteria:
• participants in “good health”,
• clinical diagnosis of irreversible pulpitis (spontaneous moderate/severe pain),
• percussion sensitivity,
• tooth vital to electric pulp tester (EPT) and painful response to Endo Ice,
• radiographically widened periodontal ligament space.
Exclusion criteria:
• tooth not responsive to EPT,
• participants taking antibiotics or in the preceding 30 days.
Interventions Oral penicillin or placebo control (lactose) and all patients received analgesics.
7-day oral dose 500mg6hourly; penicillin (PenicillinVK;Wyeth Laboratories, Philadel-
phia, Pa) or a placebo control (lactose).
Analgesics: 600 mg ibuprofen (Motrin; HN Norton Co, Shreveport, La); paracetamol
(acetaminophen) with 30 mg of codeine (Tylenol No 3; McNeil Consumer Products,
Fort Washington, Pa)
Outcomes Primary outcomes: between-group differences in sum of pain intensity difference (SPID)
, sum of pain percussion intensity difference (SPPID) and quantity of pain medications
taken
Notes There were no withdrawals or dropouts.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Before the experiment, patient
groups (penicillin or placebo)were assigned
by using 4-digit numbers from a random
number table.”
Comment: probably done.
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Nagle 2000 (Continued)
Allocation concealment (selection bias) Low risk Quote: “Only the random numbers were
recorded on the data collection and postop-
erative diary sheets to blind the experiment.
” “The medications were blinded, random-
ized, and packaged by a pharmacy.”
Comment: central randomisation, proba-
bly done.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants/healthcare providers.
Quote: “Each 500-mg gelatin capsule of
either penicillin or placebo was identical in
form. The 500-mg tablets of penicillin VK
were ground into a powder and placed into
the clear, unlabeled gelatin capsules. The
white powder of the lactose placebo was
indistinguishable from thewhite powder of
the penicillin tablets when viewed through
the capsule.”
Comment: probably done.
Outcomes assessors and data analysts.
The outcomes were self-assessed and as the
caregivers were blinded, this was probably
done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data were complete for all of the
participants.
Comment: we judged this as at low risk of
bias.
Selective reporting (reporting bias) Low risk No evidence of selective choice of data for
outcomes. Outcomes listed in the methods
section comparable to the reported results
Comment: we judged this as at low risk of
bias.
Other bias Low risk Quote: “Supported by research funding
from the Endodontic Graduate Student
Research Fund and the Steve Goldberg
Memorial Fund, The Ohio State Univer-
sity.”
Comment: appears to be free of other bias.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Fouad 1996 This study combined antibiotic or placebo or neither as an adjunct to operative endodontic treatment in resolving
the acute apical abscess
Henry 2001 This study combined antibiotic as an adjunct to endodontic treatment
Nusstein 2003 This study was a retrospective non-experimental study.
A D D I T I O N A L T A B L E S
Table 1. Baseline pain and percussion values for penicillin and placebo groups
Penicillin Placebo
Initial pain (median & interquartile range) 2.00 ± 0.00 2.00 ± 1.00
Initial percussion pain (median & in-
terquartile range)
2.00 ± 0.50 2.00 ± 1.00
Pain ratings: moderate 65% 80%
Pain ratings: severe 35% 20%
Percussion pain ratings: mild 20% 25%
Percussion pain ratings: moderate 50% 65%
Percussion pain ratings: severe 30% 10%
Table 2. Sum of pain and percussion pain intensity difference
Penicillin Placebo P value
Sum of pain intensity differ-
ence (median and interquartile
range)
6.0 ± 10.5 6.0 ± 9.5 0.776
Sum of percussion pain inten-
sity difference (median and in-
terquartile range)
3.5 ± 7.5 2.0 ± 7.0 0.290
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Table 3. Use of pain medication for penicillin and placebo groups (number and quantity)
Day Number ibuprofen Number Tylenol Nil pain medication
Day 1
Penicillin 17 (85%) 10 (50%) 1 (5%)
Number of tablets 33 21 0
Placebo 16 (80%) 8 (40%) 0
Number of tablets 28 11 0
Day 2
Penicillin 17 (85%) 10 (50%) 0
Number of tablets 30 28 0
Placebo 16 (80%) 9 (45%) 1 (5%)
Number of tablets 31 18 0
Day 3
Penicillin 13 (65%) 9 (45%) 4 (20%)
Number of tablets 27 20 0
Placebo 15 (75%) 8 (40%) 3 (15%)
Number of tablets 28 14 0
Day 4
Penicillin 12 (60%) 9 (45%) 6 (30%)
Number of tablets 24 23 0
Placebo 17 (85%) 5 (25%) 2 (10%)
Number of tablets 28 8 0
Day 5
Penicillin 12 (60%) 8 (40%) 7 (35%)
Number of tablets 21 15 0
Placebo 16 (80%) 7 (35%) 3 (15%)
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Table 3. Use of pain medication for penicillin and placebo groups (number and quantity) (Continued)
Number of tablets 32 11 0
Day 6
Penicillin 13 (65%) 8 (40%) 5 (25%)
Number of tablets 24 15 0
Placebo 13 (65%) 6 (30%) 6 (30%)
Number of tablets 24 13 0
Day 7
Penicillin 14 (70%) 10 (50%) 4 (20%)
Number of tablets 25 16 0
Placebo 11 (55%) 7 (35%) 7 (35%)
Number of tablets 20 14 0
Table 4. Research recommendations based on a gap in the evidence of the effects of antibiotics for irreversible pulpitis
Core elements Issues to consider Status of research for this review
Evidence (E) What is the current state of the evidence? This systematic review identified 1 randomised con-
trolled trial
Population (P) Diagnosis, disease stage, comorbidity, risk factors, gen-
der, age, ethnic group, specific inclusion or exclusion
criteria, clinical setting
Inclusion criteria
• Adult patients > 18 years with a single tooth with
a clinical diagnosis of irreversible pulpitis
Exclusion criteria
• If pulpectomy is to be provided immediately
Intervention (I) Type, frequency, dose, duration, prognostic factor Any systemic antibiotic at any dosage and any analgesic
at any dosage prescribed in the acute preoperative phase
of irreversible pulpitis
Comparison (C) Type, frequency, dose, duration, prognostic factor Placebo and any analgesic, at any dosage, prescribed in
the acute preoperative phase of irreversible pulpitis
Outcome (O) Which clinical or patient-related outcomes will the re-
searcher need tomeasure, improve, influence, or accom-
plish? Which methods of measurement should be used?
• Patient-reported pain (intensity/duration) and
pain relief measured on a categorical scale in the
preoperative phase of irreversible pulpitis
• Any adverse effects related to any clinically
diagnosed hypersensitivity or other reactions to either
the antibiotics or analgesics
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Table 4. Research recommendations based on a gap in the evidence of the effects of antibiotics for irreversible pulpitis
(Continued)
• Type, dose and frequency of medication required
for pain relief
Time stamp (T) Date of literature search or recommendation 18 February 2019
Study type What is the most appropriate study design to address
the proposed question?
• Randomised controlled trial (adequately
powered/multicentred)
• Methods: concealment of allocation sequence
• Blinding: participants, trialists, outcomes
assessors, data analysts
• Setting: hospital/university or general practice
with adequate follow-up
A P P E N D I C E S
Appendix 1. Cochrane Oral Health’s Trials Register search strategy
Cochrane Oral Health’s Trials Register is available via the Cochrane Register of Studies. For information on how the register is compiled,
see oralhealth.cochrane.org/trials.
From September 2013, searches of Cochrane Oral Health’s Trials Register were conducted using the Cochrane Register of Studies and
the search strategy below:
#1 ((anti-bacterial-agents OR penicillin* OR amoxicillin* OR erythromycin* OR antibiotic OR anti-biotic OR antibacterial* OR
anti-bacterial*)) AND (INREGISTER)
#2 (pulpectom*)
#3 #1 and #2
Previous searches for this review were conducted using Cochrane Oral Health’s Trials Register via the Procite software:
((anti-bacterial-agents OR penicillin* OR amoxicillin* OR erythromycin* OR antibiotic OR anti-biotic OR antibacterial* OR anti-
bacterial*) AND (pulpectom*))
Appendix 2. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
1. ANTI-BACTERIAL AGENTS
2. PENICILLINS
3. antibiotic* OR anti-biotic*
4. (antibacterial agent* OR anti-bacterial agent*)
5. antibacterial* OR anti-bacterial*
6. (penicillin* or amoxicillin or erythromycin)
7. 1 OR 2 OR 3 OR 4 OR 5 OR 6
8. PULPECTOMY
9. pulpectom*
10. (#8 or #9)
11.(#7 and #10)
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Appendix 3. MEDLINE (Ovid) search strategy
1. Anti-Bacterial Agents/
2. PENICILLINS/
3. (antibiotic$ or anti-biotic$).mp.
4. anti-bacterial-agent$.mp.
5. antibacterial agent$.mp.
6. (antibacterial$ or anti-bacterial$).mp.
7. (penicillin$ or amoxicillin$ or erythromycin$).mp.
8. or/1-7
9. PULPECTOMY/
10. pulpect$.mp.
11. or/9-10
12. 8 and 11
Appendix 4. Embase (Ovid) search strategy
1. Antibiotic Agent/
2. PENICILLIN DERIVATIVE/
3. (antibiotic$ or anti-biotic$).mp.
4. anti-bacterial-agent$.mp.
5. antibacterial agent$.mp.
6. (antibacterial$ or anti-bacterial$).mp.
7. (penicillin$ or amoxicillin$ or erythromycin$).mp.
8. or/1-7
9. pulpectom$.mp.
10. 8 and 9
Appendix 5. US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov) and World
Health Organization International Clinical Trials Registry Platform search strategy
pulpectomy and antibiotics
pulpectomy and antibacterial
pulpectomy and penicillin
pulpectomy and amoxicillin
WH A T ’ S N E W
Date Event Description
8 May 2019 New citation required but conclusions have not changed New review authors added. Backgroundupdated. Searches
updated but no new studies found. Conclusions remain
the same
8 May 2019 New search has been performed Searches updated to February 2019. No additional eligible
studies identified
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H I S T O R Y
Protocol first published: Issue 4, 2004
Review first published: Issue 2, 2005
Date Event Description
9 February 2016 New citation required but conclusions have not
changed
There were no new randomised controlled trials. Con-
clusions are the same. Change of contact person
9 February 2016 New search has been performed Searches updated to January 2016. No additional eli-
gible studies identified
17 December 2013 New citation required but conclusions have not
changed
New review authors added. Modifications in text and
style in conformity with Methodological Expectations
of Cochrane Intervention Reviews (MECIR) stan-
dards
6 September 2013 New search has been performed Searches updated to September 2013. No additional
eligible studies identified
16 February 2009 New search has been performed New searches: February 2009. New studies sought but
none found. Text in ’Assessment of risk of bias in in-
cluded studies’ modified. Risk of bias table added
8 August 2008 Amended Converted to new review format.
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